Jherek Swanger

Jherek Swanger

Auto-generated profile, based on publicly available information

Jherek Swanger

Clinical Research Division, Fred Hutchinson Cancer Research Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Science Advances
Verified
Journal Article
Open access
MWMarkus Welcker
Markus Welcker
BWBaiyun Wang
Baiyun Wang
DRDomniţa-Valeria Rusnac
Domniţa-Valeria Rusnac
YHYasser Hussaini
Yasser Hussaini
JSJherek Swanger
Jherek Swanger
BCBruce E. Clurman
Bruce E. Clurman
C-Myc (hereafter, Myc) is a cancer driver whose abundance is regulated by the SCF Fbw7 ubiquitin ligase and proteasomal degradation. Fbw7 binds to a phosphorylated Myc degron centered at threonine 58 (T58), and mutations of Fbw7 or T58 impair Myc degradation in cancers. Here, we identify a second Fbw7 phosphodegron at Myc T244 that is required for Myc ubiquitylation and acts in concert with T58 to engage Fbw7. While Ras-dependent Myc serine 62 phosphorylation (pS62) is thought to stabilize Myc by preventing Fbw7 binding, we find instead that pS62 greatly enhances Fbw7 binding and is an integral part of a high-affinity degron. Crystallographic studies revealed that both degrons bind Fbw7 in their diphosphorylated forms and that the T244 degron is recognized via a unique mode involving Fbw7 arginine 689 (R689), a mutational hotspot in cancers. These insights have important implications for Myc-associated tumorigenesis and therapeutic strategies targeting Myc stability.

22 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ADAhmed Diab
Ahmed Diab
HGHakan Gem
Hakan Gem
JSJherek Swanger
Jherek Swanger
HKHee Yeon Kim
Hee Yeon Kim
KSKaleb Smith
Kaleb Smith
BCBruce E. Clurman
Bruce E. Clurman
Significance: HPV+ HNSCC is a growing problem in the United States. We show that HPV16 E6/E7 render HNSCC sensitive to WEE1 inhibition through a CDK1-FOXM1 circuit that drives premature mitosis and requires E6 activities beyond p53 inactivation. Primary HPV+ HNSCCs exhibit high FOXM1 activity, which may underlie their sensitivity to WEE1 inhibition. These data provide a mechanistic rationale for WEE1i incorporation into HPV+ HNSCC treatment.